Max, a 9-year-old golden retriever, used to nap all day. He drank constantly, lost weight, and stopped chasing balls. His vet said it was early kidney disease — a slow, silent decline many dogs face. Most live less than a year after diagnosis. But Max started a new treatment. Three years later, he’s back on long walks, tail wagging, and eating with gusto.
Kidney disease is one of the most common serious health problems in older dogs. Once it starts, it rarely stops. About 1 in 10 dogs will develop it, and there are few drugs that truly slow it down. Most treatments focus on diet and managing symptoms. But they don’t change the outcome much.
Now, a small but powerful study is turning heads.
A drug already used in cats may help dogs live much longer
For years, vets have had few real tools to fight dog kidney disease. The goal has always been to delay the worst — weakness, nausea, and early death. But here’s the twist: a drug called beraprost, approved for cats with kidney disease, may do something rare — actually extend life in dogs.
This isn’t just about feeling better. It’s about living longer.
Think of the kidneys like a city’s water treatment plant. They filter waste, balance fluids, and keep the body clean. In kidney disease, the filters slowly clog. Blood flow drops. Toxins build up. But beraprost works like a traffic director for blood vessels. It opens up tiny arteries in the kidneys, improving flow and reducing damage — like clearing a blocked pipe before the whole system fails.
The study followed 16 dogs with early-stage kidney disease who took beraprost twice daily. They were compared to 17 similar dogs from the same clinic who didn’t get the drug. All had IRIS stage 2 disease — not yet severe, but on the path to decline.
The results stunned even the researchers.
Dogs on beraprost lived a median of 1,101 days — nearly three years. The untreated group lived just 198 days. That’s a 5.6-fold increase. More than five times longer.
They also stayed healthier longer. The drug delayed disease worsening, weight loss, and death. Even after adjusting for age and protein in urine — two strong predictors of survival — beraprost was the only factor that clearly improved outcomes.
But there's a catch.
This wasn’t a randomized trial. The treated dogs were followed forward in time, but the comparison group came from past records. That means other unknown factors could play a role. Still, the groups were closely matched. And the size of the benefit is too large to ignore.
This doesn't mean this treatment is available yet.
Experts say the findings are promising but not final. “We’ve never seen a drug show this kind of survival boost in early kidney disease,” said one veterinary nephrologist not involved in the study. “It suggests we might finally have a way to change the course of the disease, not just manage it.”
So what does this mean for dog owners?
If your dog has early kidney disease, beraprost may be an option — but only under a vet’s care. It’s not yet approved for dogs in most countries and is used off-label. That means it’s prescribed based on clinical judgment, not official approval. Side effects were mild in the study, but not all dogs respond the same.
The study was small — just 33 dogs total. And it was done at a single clinic. That limits how widely the results can be applied right now. Also, all dogs were carefully monitored, which may have helped outcomes.
The road ahead? A large, randomized trial is the next step. Researchers need to confirm these results in more dogs, across different clinics, with strict controls. If they do, beraprost could become a standard early treatment.
For now, the message is hope — not a guarantee. But for dogs like Max, and the families who love them, even a chance at more time is priceless.
More studies are underway. Approval could take years. But for the first time, vets have real evidence that early kidney disease in dogs might not have to mean a short countdown.
It might mean more walks. More naps in the sun. More years together.
